In a landmark new collaboration, the CBD by BRITISH CANNABIS™ range of pharmacy-quality CBD food supplements is set to become available on prescription to pain patients for the first time in the UK.
BRITISH CANNABIS™ is proud to announce its partnership with Treat It, a pioneering online pain management clinic from Kanabo. Treat It provides eligible patients with access to a range of medicinal cannabis treatments.
This collaboration marks a significant milestone, enabling prescribing doctors to provide CBD by BRITISH CANNABIS™ products for long-term pain management, including high-strength CBD oils and locally targeted CBD patches.
With a strong reputation built over seven years, CBD by BRITISH CANNABIS™ has been trusted by pharmacists and garnered thousands of positive reviews from users on Trustpilot. This partnership extends the reach of CBD products to qualifying patients through a prescription-based model.
Focused on secondary care, the Treat It platform enables patients access to healthcare professionals via its secure, digital healthcare platform. These medical professionals deliver a full diagnosis as part of a personalised patient care plan and are able to offer treatments, including the prescription of medicinal cannabis, for individuals seeking relief from chronic pain.
CBD, or cannabidiol, has gained considerable recognition for its potential therapeutic benefits in managing various health conditions. While traditionally associated with recreational cannabis, CBD derived from hemp contains minimal THC levels, ensuring it does not induce psychoactive effects. As a result, CBD has emerged as a promising treatment option for individuals seeking non-pharmaceutical approaches to pain management.
Through the collaboration between BRITISH CANNABIS™ and Treat It, doctors can offer patients access to high-quality supplements. These products have proven effective in alleviating symptoms associated with long-term pain issues, providing an alternative pathway to pharmaceutical care.
“We are thrilled to join forces with Treat It to make CBD products from our long-standing pharmacy retail brand accessible to pain patients through prescriptions,” says Steve Batchelor, BRITISH CANNABIS™ Marketing Director.
“This partnership represents a significant step forward in expanding patient choices and empowering doctors to explore naturally-derived supplements, as alternatives to traditional pharmaceutical care paths. We are also pleased that thousands of long-term CBD customers will have the option to consult with Treat It’s network of specialist pain doctors, assessing their own particular needs and determining things like what delivery formats, when and how much CBD they could be taking.”
Treat It, the innovative online clinic founded by Kanabo, seeks to revolutionise healthcare by adopting a patient-centric approach to telemedicine. The platform allows patients to conveniently consult with healthcare professionals and access personalised treatment recommendations from the comfort of their own homes. By incorporating CBD by BRITISH CANNABIS™ products into their offerings, Treat It continues to break down barriers and champion patient wellbeing.
The patient pathway for raising awareness of these prescription products will also be boosted by the launch of Canndr – a medicinal cannabis app and patient supporting tech company from the founders of BRITISH CANNABIS™. From November 2023, patients will be able to select and review quality cannabis medicines on the market, gain consultancy advice and select from a number of suitable CBMP prescribing clinics, including Treat It.
The accessibility of CBD by BRITISH CANNABIS™ products, combined with the expertise and convenience of Treat It’s platform makes this partnership a paradigm shift for patients. By offering CBD via prescription services , this collaboration allows doctors to provide comprehensive care that aligns with patients’ individual needs and preferences.
Kanabo CEO, Avihu Tamir commented: “At Kanabo, we aim to increase medicinal cannabis access for more patients. This partnership allows Treat It doctors to include a wider range of quality CBD supplements in our telemedicine offerings. We’re eager to further enhance patient-centric healthcare and treatment options. This partnership is just the beginning, and we hope to announce more expansive collaborations in due course.”
BRITISH CANNABIS™ and Treat It aim to positively empower both doctors and patients to explore natural alternatives and improve overall quality of life.
For media inquiries, please contact firstname.lastname@example.org or email@example.com.
BRITISH CANNABIS™ are pioneers in the UK cannabis industry since 2015, specialising in high-quality CBD products trusted by business, pharmacies and over 40,000 consumers alike. With over seven years of experience and a strong reputation, BRITISH CANNABIS™ is dedicated to providing natural wellness solutions and promoting education surrounding CBD.
The largest manufacturer of CBD food supplements in the UK today, as confirmed by having more registered products on the FSA Novel Food list than any other manufacturer. As well as award-winning CBD brands, BRITISH CANNABIS™ also offer class-leading white label and private label manufacturing services for some of the industry’s biggest product ranges; as well as bulk ingredient services, regulatory compliance consultancy and even grow Cannabis sativa L. at their own farm in Europe.
About Kanabo Group plc
Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Kanabo’s NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It – an online clinic focused on chronic pain management providing patients with secondary care.
With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider, offering telehealth consultations, prescriptions, alongside the delivery of tailored treatments.
The Company’s partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo’s formulas and product line.
At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.
Visit www.kanabogroup.com for more information.
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- Cannabis more ‘advantageous’ than conventional sleep aids
- Four20 Medical Cannabis Products Launched in the UK via Rokshaw
- The potential of Medical Cannabis in diabetes management
- Cannabis explained6 months ago
What is HHC? Its effects, safety and legal status in Europe
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Industry6 months ago
UK’s first ‘own your grow’ initiative gives patients chance to invest in cannabis
- Advocacy5 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
Hemp tea no longer classed as Novel Food under EU law